Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.

Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE

Original Publication: [London] : BMJ Publishing Group Ltd, 2011-

Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/*therapeutic use; Drug Combinations ; Drug Substitution ; Female ; Humans ; Japan ; Male ; Medication Adherence ; Middle Aged ; Retrospective Studies ; Treatment Outcome

Objective: To determine real-world trends in antidiabetic drug use, and persistence and adherence, in Japanese patients with type 2 diabetes mellitus (T2DM).
Design: Retrospective evaluation of administrative claims data (2011-2015) using the Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases.
Setting: Analysis of two administrative claims databases for Japanese patients with T2DM.
Participants: Adults (aged ≥18 years) with an International Classification of Diseases, 10th Revision code of T2DM and at least one antidiabetic drug prescription.
Main Outcome Measures: Treatment patterns in untreated (UT) or previously treated (PT) patients receiving antidiabetic therapy; persistence with treatment at 12 months; adherence to treatment at 12 months.
Results: 40 908 and 90 421 patients were included from the JMDC and MDV databases, respectively. The most frequently prescribed therapy at the index (first prescription) date was dipeptidyl peptidase-4 inhibitor (DPP-4i) in UT patients (JMDC: 44.0%, MDV: 54.8%) and combination therapy in PT patients (74.6%, 81.1%). Most common combinations were DPP-4i plus: biguanide (BG; 11.4%, 10.9%), sulfonylurea (SU; 8.4%, 11.0%) or BG+SU (7.8%, 9.1%). In UT or PT patients from either database whose index prescription was for any antidiabetic drug class(es) other than DPP-4i, the most frequent add-on or switch was to DPP-4i. 12-month persistence with index monotherapy was highest with DPP-4i and BG. Adherence was high (≥80%) for all monotherapy schedules, except insulin and glucagon-like peptide-1 agonist, and for the five most frequent two-drug and three-drug combinations. Persistence was greater in elderly UT patients and in those receiving ≤5 medications, but comparatively worse in UT patients with ≥3 index antidiabetic drug classes.
Conclusions: The findings indicate that DPP-4i is the most commonly used antidiabetic drug class in Japanese patients with T2DM, and persistence and adherence to this antidiabetic drug class are high.
Competing Interests: Competing interests: RN has received speaker honoraria from Astellas Pharma, Nippon Boehringer Ingelheim, Eli Lilly Japan K.K., Kissei Pharmaceutical, Medtronic Japan, MSD, Novartis Pharma KK, Novo Nordisk Pharma, Sanofi KK and Takeda Pharmaceutical and contract research fees for collaborative research with the Japan Diabetes Foundation. HK, KK, AO and YS are employees of Takeda Pharmaceutical. SH was an employee of Takeda Pharmaceutical at the time the study was conducted. FG and YO are employees of Creativ-Ceutical K.K.
(© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

J Diabetes Investig. 2012 Dec 20;3(6):498-502. (PMID: 24843614)
N Engl J Med. 2013 Oct 3;369(14):1317-26. (PMID: 23992601)
Diabetol Metab Syndr. 2016 Nov 10;8:72. (PMID: 27843494)
J Clin Med Res. 2016 Feb;8(2):130-40. (PMID: 26767082)
J Diabetes. 2017 Jul;9(7):677-688. (PMID: 27531167)
Lancet Diabetes Endocrinol. 2015 Mar;3(3):191-7. (PMID: 25609193)
N Engl J Med. 2005 Aug 4;353(5):487-97. (PMID: 16079372)
Mayo Clin Proc. 2011 Apr;86(4):304-14. (PMID: 21389250)
Diabetologia. 2012 Jun;55(6):1577-96. (PMID: 22526604)
BMJ Open Diabetes Res Care. 2016 Sep 09;4(1):e000291. (PMID: 27651912)
N Engl J Med. 2013 Oct 3;369(14):1327-35. (PMID: 23992602)
Intern Med. 2017 Oct 1;56(19):2563-2569. (PMID: 28883229)
Diabetes Obes Metab. 2018 Jun;20(6):1427-1434. (PMID: 29405540)
J Diabetes Investig. 2016 Apr;7 Suppl 1:102-9. (PMID: 27186364)
Cardiovasc Diabetol. 2017 Mar 1;16(1):31. (PMID: 28249585)
Expert Opin Pharmacother. 2015;16(16):2539-47. (PMID: 26523434)
Diabetes Res Clin Pract. 2017 Jan;123:55-62. (PMID: 27940390)
Endocr J. 2018 Feb 26;65(2):141-150. (PMID: 29093280)
J Clin Med Res. 2017 Aug;9(8):719-724. (PMID: 28725321)
Diabetes Obes Metab. 2018 Apr;20(4):1040-1043. (PMID: 29135080)
Diabetes Care. 2015 Jan;38(1):140-9. (PMID: 25538310)
Diabetes Obes Metab. 2015 Apr;17(4):430-4. (PMID: 25146418)
N Engl J Med. 2014 Feb 27;370(9):794-7. (PMID: 24571751)
Diabetes Obes Metab. 2014 Oct;16(10):900-9. (PMID: 24655583)
Nagoya J Med Sci. 2017 Aug;79(3):313-321. (PMID: 28878436)
Clin Pharmacol Ther. 2017 Oct;102(4):701-708. (PMID: 28378919)
J Diabetes Investig. 2018 Jan;9(1):137-145. (PMID: 28296349)
Diabetologia. 2013 Apr;56(4):696-708. (PMID: 23344728)
J Diabetes Investig. 2016 Sep;7(5):737-43. (PMID: 27182033)
Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. (PMID: 29079252)
J Atheroscler Thromb. 2014;21(2):93-8. (PMID: 24335040)
Diabetes Care. 2012 Jun;35(6):1364-79. (PMID: 22517736)
Am J Manag Care. 2008 Feb;14(2):71-5. (PMID: 18269302)
J Diabetes Investig. 2012 Oct 18;3(5):464-7. (PMID: 24843607)
Diabetes Care. 2017 Feb;40(2):161-163. (PMID: 28108536)
J Diabetes Investig. 2017 Jan;8(1):123-125. (PMID: 27935263)

Keywords: adherence; administrative claims-based study; antidiabetic drug therapy; dipeptidyl peptidase-4 inhibitors; persistence; type 2 diabetes

0 (Drug Combinations)
0 (Hypoglycemic Agents)

Date Created: 20190304 Date Completed: 20200330 Latest Revision: 20220409

20221213

PMC6429930

10.1136/bmjopen-2018-025806

30826768